3SBio, Inc. (ADR) (NASDAQ:SSRX)

SapphireSeas (73.14) Submitted: 9/29/2007 12:00:11 PM : Start Price: $15.34 SSRX Score: -5.69

IPO on Nasdaq in February, with proposed range of $12 to $14 / share. Initial Offering exceeded expectations at $16 per share, subsequently climbing to $18.

CIBC World Markets is predicting earnings for 3SBio will quadruple by 2009, with profit of $1.13 per share at that time, up from 27 cents in 2006.

SSRX's main revenue producer is EPIAO, which is used to treat anemia associated with chemotherapy and kidney dialysis. CIBC believes the market for this drug is underserved in China, with much room to grow.

squrl020 (< 20) Submitted: 9/13/2007 9:14:58 AM : Start Price: $11.33 SSRX Score: +21.48

lots of aging people need advancing biotech

ohkrlll (< 20) Submitted: 8/2/2007 3:01:48 AM : Start Price: $8.79 SSRX Score: +53.60

52% LT growth china leading biotech

nguyenvanh (< 20) Submitted: 6/29/2007 5:24:15 PM : Start Price: $9.68 SSRX Score: +42.54

China growh, stable revenues/earnings.

rnetas (< 20) Submitted: 6/1/2007 7:21:14 AM : Start Price: $11.61 SSRX Score: +21.56

cool

liuyan (< 20) Submitted: 3/21/2007 5:38:24 PM : Start Price: $12.50 SSRX Score: +6.98

A leading biotech firm in China, with four products in hand. How many biotech firms have that many products here in the US? A very small number of firms such as Amgen, DNA and Gilead. The flagship product is a mimic of Amgen's EPO, for sure it will deliver huge increase of sell. With market cap is only less than 300 Mill, we should see it goes up to 3 Bill in several years. Lets see it plays in the next 6 months.

nau99 (29.31) Submitted: 3/6/2007 5:54:01 PM : Start Price: $12.50 SSRX Score: +3.88

In the very short-term this stock freaks me out. Beyond the next 1-2 weeks the China scare will lessen and the price will soar like the population.

rbhoit (< 20) Submitted: 3/4/2007 5:01:31 PM : Start Price: $12.47 SSRX Score: +2.91

The products made and sold by 3Sbio in China are similar to blockbuster meds sold by Amgen. I suspect China will allow continued sales (company has been in existence sine 1994) and the marked for a &quot;home grown&quot; chinese product may well be a sales plus when competing against Amgen products there in China.